BioCentury | Aug 24, 2009
Finance

Ebb & Flow

Having granted U.S. marketing rights to Intermezzo zolpidem to Purdue Pharma L.P. earlier this month, Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) last week said it would cut the staff made superfluous by the deal. It will trim...
BioCentury | Sep 11, 2006
Strategy

Biotech accumulators

It is becoming increasingly clear that investors in the European biotech sector are becoming much more discerning. No longer is it enough to have a promising clinical candidate to attract finance. Investors are backing companies...
BC Week In Review | Sep 12, 2005
Company News

SpinX Technologies SA board of directors update

SpinX Technologies SA , Geneva, Switzerland   Business: Supply/Service   Appointed: Seppo Maekinen, senior partner at BioFund Management; Philippe Peltier, partner at Auriga Partners; and Mir Imran, venture partner and advisor at DFJ ePlanet  ...
BioCentury | Oct 20, 2003
Strategy

Europe's spinning wheel

Corporate spinouts are classically done by established companies that want to maintain a core focus. Over the past three years, at least a dozen European biotech companies have done spinouts. In addition to the conventional...
Items per page:
1 - 4 of 4
BioCentury | Aug 24, 2009
Finance

Ebb & Flow

Having granted U.S. marketing rights to Intermezzo zolpidem to Purdue Pharma L.P. earlier this month, Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) last week said it would cut the staff made superfluous by the deal. It will trim...
BioCentury | Sep 11, 2006
Strategy

Biotech accumulators

It is becoming increasingly clear that investors in the European biotech sector are becoming much more discerning. No longer is it enough to have a promising clinical candidate to attract finance. Investors are backing companies...
BC Week In Review | Sep 12, 2005
Company News

SpinX Technologies SA board of directors update

SpinX Technologies SA , Geneva, Switzerland   Business: Supply/Service   Appointed: Seppo Maekinen, senior partner at BioFund Management; Philippe Peltier, partner at Auriga Partners; and Mir Imran, venture partner and advisor at DFJ ePlanet  ...
BioCentury | Oct 20, 2003
Strategy

Europe's spinning wheel

Corporate spinouts are classically done by established companies that want to maintain a core focus. Over the past three years, at least a dozen European biotech companies have done spinouts. In addition to the conventional...
Items per page:
1 - 4 of 4